Prokarium acquires key oral vaccine technology from Emergent BioSolutions

13-Jul-2012 - United Kingdom

Prokarium Ltd, a spin-out company of Cobra Biologics, completed a key technology acquisition from Emergent BioSolutions Inc. The technology includes Emergent’s live Salmonella-based typhoid vaccine TyphellaTM and its genetic technology spi-VECTM. Prokarium will combine TyphellaTM and spi-VECTM with its proprietary genetic and formulation technologies to form VaxonellaTM, an oral vaccine delivery platform.

Emergent has successfully conducted several phase 1 and 2 clinical trials, which have shown TyphellaTM to be safe and immunogenic as a typhoid vaccine. The combination with Prokarium’s plasmid stabilisation technology ORT-VACTM, will enable the delivery of recombinant protein vaccines without needles or adjuvants. Prokarium plans to offer this VaxonellaTM platform to the biotech community on a licensing basis.

Prokarium will focus on the development of a dual oral vaccine against typhoid and ETEC (enterotoxigenic E. coli) for travellers and developing country markets.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances